Get the Stockscreener App
23.22
9.67%
-2.485
Pre-market:
23.14
-0.08
-0.34%
Procept Biorobotics Corp stock is traded at $23.22, with a volume of 3.21M.
It is down -9.67% in the last 24 hours and down -11.10% over the past month.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
See More
Previous Close:
$25.70
Open:
$25.28
24h Volume:
3.21M
Relative Volume:
2.26
Market Cap:
$1.32B
Revenue:
$322.02M
Net Income/Loss:
$-102.47M
P/E Ratio:
-12.69
EPS:
-1.8295
Net Cash Flow:
$-80.57M
1W Performance:
-18.10%
1M Performance:
-11.10%
6M Performance:
-35.68%
1Y Performance:
-61.70%
1-Day Range:
$22.47
$25.45
1-Week Range:
$22.47
$29.74
52-Week Range:
$19.35
$62.17
Procept Biorobotics Corp Stock (PRCT) Company Profile
Name
Procept Biorobotics Corp
Sector
Industry
Phone
(650) 232-9832
Address
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
23.22 | 1.32B | 322.02M | -102.47M | -80.57M | -1.8295 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Initiated | Robert W. Baird | Neutral |
| Feb-26-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-26-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-12-25 | Initiated | UBS | Buy |
| Dec-08-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-02-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-09-25 | Initiated | Stephens | Overweight |
| Jul-07-25 | Initiated | Oppenheimer | Perform |
| Dec-02-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Initiated | Jefferies | Hold |
| Aug-11-23 | Initiated | Piper Sandler | Overweight |
| May-31-23 | Initiated | William Blair | Outperform |
| Oct-31-22 | Initiated | BTIG Research | Neutral |
| Oct-25-22 | Initiated | Truist | Buy |
| Sep-02-22 | Initiated | Wells Fargo | Overweight |
| Jul-15-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Goldman | Neutral |
| Oct-11-21 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Procept Biorobotics Corp Stock (PRCT) Latest News
Why is Procept Biorobotics stock sliding today? By Investing.com - Investing.com South Africa
Why is Procept Biorobotics stock sliding today? - Investing.com
Procept BioRobotics shares slide after Leerink downgrade cites rising competitive risks - MSN
PROCEPT BioRobotics Shares Drop After Downgrade From Leerink Partners - marketscreener.com
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Leerink downgrades Procept BioRobotics stock rating on competition - Investing.com UK
Leerink downgrades Procept BioRobotics stock rating on competition By Investing.com - Investing.com Canada
Procept BioRobotics EVP Nouri Alaleh sells $8,116 in stock By Investing.com - Investing.com Australia
Procept BioRobotics EVP Nouri Alaleh sells $8,116 in stock - Investing.com
PROCEPT BioRobotics (PRCT) director receives RSU and option grants as equity pay - Stock Titan
Director Amy Dodrill receives RSUs and options at PROCEPT (NASDAQ: PRCT) - Stock Titan
PROCEPT BioRobotics (PRCT) director Mary Garrett granted RSUs and options - Stock Titan
Director at PROCEPT BioRobotics (PRCT) receives new RSU and option awards - Stock Titan
Director at PROCEPT BioRobotics (PRCT) receives RSU and stock option grants - Stock Titan
Director Frederic Moll of PROCEPT BioRobotics (PRCT) granted RSUs and options - Stock Titan
PROCEPT BioRobotics (PRCT) director receives new RSU and stock option grants - Stock Titan
Director at PROCEPT (PRCT) granted RSUs and stock options - Stock Titan
PROCEPT BioRobotics (NASDAQ: PRCT) reports 2026 shareholder vote outcomes - Stock Titan
[Form 4] PROCEPT BioRobotics Corp Insider Trading Activity - Stock Titan
PRCT (NASDAQ: PRCT) files Form 144 for 285-share sale after vesting - Stock Titan
PRCT (NASDAQ) Rule 144 notice: Director activity, 357 vested shares reported - Stock Titan
PRCT (NASDAQ) insider sale notice — 358 vested shares to be sold - Stock Titan
PROCEPT BioRobotics (PRCT) Is Up 5.7% After New WATER IV Trials Expand Aquablation Testing Scope - simplywall.st
Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment - MSN
Baird initiates Procept BioRobotics stock rating at Neutral - Investing.com
Procept BioRobotics appoints Daniel Puckett to board and audit committee - Investing.com
PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV MilestonesWhat's Changed - Yahoo Finance
PROCEPT BioRobotics (PRCT) Is Down 6.0% After WATER IV Trial Milestones – Has The Bull Case Changed? - simplywall.st
Procept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollment - MassDevice
Siemens Healthineers, AiM team up; Procept completes study enrollment - Yahoo Finance
PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE Approval - marketscreener.com
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval - markets.businessinsider.com
Procept BioRobotics completes enrollment in prostate cancer study By Investing.com - Investing.com South Africa
Procept BioRobotics completes enrollment in prostate cancer study - Investing.com
PROCEPT BioRobotics® Advances Prostate Cancer Program with - GlobeNewswire
A Look At PROCEPT BioRobotics (PRCT) Valuation After Its Better Than Expected Q1 Earnings And Analyst Updates - simplywall.st
Here’s What the Street Thinks About PROCEPT BioRobotics Corporation (PRCT) - Insider Monkey
PROCEPT BioRobotics Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressGross Profit Margin - The League of Women Voters of Texas
Lisanti Capital Growth LLC Buys Shares of 35,890 PROCEPT BioRobotics Corporation $PRCT - MarketBeat
DNB Asset Management AS Has $3.13 Million Stock Position in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
Will Stronger AUA Aquablation Guidelines Across Prostate Sizes Change PROCEPT BioRobotics' (PRCT) Narrative? - simplywall.st
AllianceBernstein (PRCT) discloses 147,327 shares; 0.3% stake reported - Stock Titan
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity - Sahm
Procept Biorobotics Corp Stock (PRCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):